c-Abl Mediates α-Synuclein Toxicity: A Promising Therapeutic Target in Parkinson's Disease and α-Synucleinopathies

被引：0

作者：

Brahmachari, S. ^{[1
,2
,3
]}

Mao, X. ^{[1
,2
,3
]}

Karuppagounder, S. S. ^{[1
,2
,3
]}

Lee, Y. ^{[1
,2
,3
]}

Dawson, V. L. ^{[1
,2
,3
,4
,5
,6
]}

Ko, H. S. ^{[1
,2
,7
]}

Dawson, T. M. ^{[1
,2
,6
,7
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA

[2] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA

[3] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA USA

[4] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Stem Cell Programs, Baltimore, MD USA

[5] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA

[6] Johns Hopkins Univ, Sch Med, Solomon H Snyder Dept Neurosci, Baltimore, MD USA

[7] Diana Helis Henry Med Res Fdn, New Orleans, LA USA

来源：

CELL TRANSPLANTATION | 2014年 / 23卷 / 06期

关键词：

D O I：

暂无

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

引用

页码：764 / 764

页数：1

共 50 条

[31] A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease
Kwon, Seung-Hwan
Kim, Sangjune
Park, A. Yeong
Lee, Saebom
Gadhe, Changdev Gorakshnath
Seo, Bo Am
Park, Jong-Sung
Jo, Suyeon
Oh, Yumin
Kweon, Sin Ho
Ma, Shi-Xun
Kim, Wonjoong R.
Kim, Misoon
Kim, Hyeongjun
Kim, Jae Eun
Lee, Seulki
Lee, Jinhwa
Ko, Han Seok
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (20) : 15091 - 15110
[32] The identification of c-Abl inhibitors as potential agents for Parkinson's disease: a preliminary in silico approach
Rymbai, Emdormi
Roy, Dhritiman
Jupudi, Srikanth
Srinivasadesikan, Venkatesan
MOLECULAR DIVERSITY, 2024,
[33] The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis
Imamura, Keiko
Izumi, Yuishin
Watanabe, Akira
Tsukita, Kayoko
Woltjen, Knut
Yamamoto, Takuya
Hotta, Akitsu
Kondo, Takayuki
Kitaoka, Shiho
Ohta, Akira
Tanaka, Akito
Watanabe, Dai
Morita, Mitsuya
Takuma, Hiroshi
Tamaoka, Akira
Kunath, Tilo
Wray, Selina
Furuya, Hirokazu
Era, Takumi
Makioka, Kouki
Okamoto, Koichi
Fujisawa, Takao
Nishitoh, Hideki
Homma, Kengo
Ichijo, Hidenori
Julien, Jean-Pierre
Obata, Nanako
Hosokawa, Masato
Akiyama, Haruhiko
Kaneko, Satoshi
Ayaki, Takashi
Ito, Hidefumi
Kaji, Ryuji
Takahashi, Ryosuke
Yamanaka, Shinya
Inoue, Haruhisa
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (391)
[34] Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Menon, Sindhu
Armstrong, Sabrina
Hamzeh, Amir
Visanji, Naomi P.
Sardi, Sergio Pablo
Tandon, Anurag
FRONTIERS IN NEUROLOGY, 2022, 13
[35] Skin nerve α-synuclein deposits in Parkinson's disease and other synucleinopathies: a review
Donadio, Vincenzo
CLINICAL AUTONOMIC RESEARCH, 2019, 29 (06) : 577 - 585
[36] Skin nerve α-synuclein deposits in Parkinson’s disease and other synucleinopathies: a review
Vincenzo Donadio
Clinical Autonomic Research, 2019, 29 : 577 - 585
[37] Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease
Labandeira-Garcia, Jose L.
Rodriguez-Perez, Ana I.
Villar-Cheda, Begona
Borrajo, Ana
Dominguez-Meijide, Antonio
Guerra, Maria J.
NEUROSCIENTIST, 2015, 21 (06): : 616 - 629
[38] Th17 cells: a promising therapeutic target for Parkinson's disease?
Prots, Iryna
Winner, Beate
EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (04) : 309 - 314
[39] Modulating Mitochondrial Pyruvate Carrier: A Promising Therapeutic Target in Parkinson's Disease
Orgaz, Lorena
Bueno Gil, Guillermo
MOVEMENT DISORDERS, 2017, 32 (05) : 719 - 719
[40] α-Synuclein is a pathological link and therapeutic target for Parkinson's disease and traumatic brain injury
Shahaduzzaman, Md
Acosta, Sandra
Bickford, Paula C.
Borlongan, Cesar V.
MEDICAL HYPOTHESES, 2013, 81 (04) : 675 - 680

← 1 2 3 4 5 →